Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8491 to 8505 of 9079 results

  1. Liposomal vincristine for treating Philadelphia chromosome-negative acute lymphoblastic leukaemia after two therapies [ID954]

    Discontinued Reference number: GID-TA11181

    Technology appraisal guidance
    Discontinued

  2. Belatacept for the prevention of organ rejection in kidney transplantation [ID87]

    Discontinued Reference number: GID-TAG239

    Technology appraisal guidance
    Discontinued

  3. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued Reference number: GID-TAG330

    Technology appraisal guidance
    Discontinued

  4. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued Reference number: GID-TAG337

    Technology appraisal guidance
    Discontinued

  5. Pazopanib for the maintenance treatment of epithelial ovarian, fallopian and peritoneal cancer [ID545]

    Discontinued Reference number: GID-TAG444

    Technology appraisal guidance
    Discontinued

  6. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    Discontinued Reference number: GID-TA10502

    Technology appraisal guidance
    Discontinued

  7. Diagnostic services

    Discontinued Reference number: GID-CGWAVE0773

    NICE guideline
    Discontinued

  8. Reducing the mortality and morbidity for healthcare associated infections

    Discontinued Reference number: GID-NG10059

    NICE guideline
    Discontinued

  9. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

    Technology appraisal guidance
    Discontinued

  10. Vandetanib for the second line treatment of non-small cell lung cancer [ID46]

    Discontinued Reference number: GID-TAG405

    Technology appraisal guidance
    Discontinued

  11. Contusugene ladenovec for the treatment of recurrent unresectable squamous cell carcinoma of the head and neck [ID76]

    Discontinued Reference number: GID-TAG407

    Technology appraisal guidance
    Discontinued

  12. Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

    Discontinued Reference number: GID-TA10698

    Technology appraisal guidance
    Discontinued

  13. Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

    Discontinued Reference number: GID-TA10702

    Technology appraisal guidance
    Discontinued

  14. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued Reference number: GID-TA10722

    Technology appraisal guidance
    Discontinued

  15. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued Reference number: GID-TA10763

    Technology appraisal guidance
    Discontinued